{
    "root": "83a474ed-d005-435f-8ff9-415d4a53ffd6",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "Dextrose and Electrolyte No. 48",
    "value": "20200213",
    "ingredients": [
        {
            "name": "DEXTROSE MONOHYDRATE",
            "code": "LX22YL083G"
        },
        {
            "name": "SODIUM LACTATE",
            "code": "TU7HW0W0QT"
        },
        {
            "name": "POTASSIUM CHLORIDE",
            "code": "660YQ98I10"
        },
        {
            "name": "MAGNESIUM CHLORIDE",
            "code": "02F3473H9O"
        },
        {
            "name": "POTASSIUM PHOSPHATE, MONOBASIC",
            "code": "4J9FJ0HL51"
        },
        {
            "name": "SODIUM CHLORIDE",
            "code": "451W47IQ8X"
        },
        {
            "name": "WATER",
            "code": "059QF0KO0R"
        }
    ],
    "indications": "5 % dextrose electrolyte . 48 injection ( multiple electrolytes dextrose injection , type 1 , usp ) indicated source water , electrolytes , calories alkalinizing agent .",
    "contraindications": "important instructions •5 % dextrose electrolyte . 48 injection ( multiple electrolytes dextrose injection , type 1 , usp ) intended intravenous using sterile equipment . •do connect flexible plastic containers series order avoid air embolism due possible residual air contained primary container . •set vent closed position vented intravenous set prevent air embolism . •use dedicated line without connections avoid air embolism . •do pressurize intravenous solutions contained flexible plastic containers increase flow rates order avoid air embolism due incomplete evacuation residual air container . •prior infusion , visually inspect solution particulate matter discoloration . solution clear precipitates . administer unless solution clear , container undamaged . •do administer 5 % dextrose electrolyte . 48 injection ( multiple electrolytes dextrose injection , type 1 , usp ) simultaneously blood set possibility pseudoagglutination hemolysis . dosing information choice product , , volume , rate , duration dependent upon age , weight condition patient concomitant therapy , determined physician experienced intravenous fluid therapy . introduction additives additives may incompatible . evaluate additions plastic container compatibility stability resulting preparation . consult pharmacist , available . , informed judgment physician , deemed advisable introduce additives , aseptic technique . mix thoroughly additives introduced . addition , discoloration and/or appearance precipitates , insoluble complexes crystals , . store solutions containing additives . discard unused portion .",
    "warningsAndPrecautions": "5 % dextrose electrolyte . 48 injection ( multiple electrolytes dextrose injection , type 1 , usp ) viaflex plastic containers available shown : code size ( ml ) ndc 2b2103 500 ndc 0338-0143-03 exposure pharmaceutical products heat minimized . avoid excessive heat . recommended product stored room temperature ( 25°c ) ; brief exposure 40°c adversely affect product .",
    "adverseReactions": "5 % dextrose electrolyte . 48 injection ( multiple electrolytes dextrose injection , type 1 , usp ) contraindicated patients •with known hypersensitivity product ( ) •with clinically significant hyperglycemia ( )",
    "indications_original": "5% Dextrose and Electrolyte No. 48 Injection (Multiple Electrolytes and Dextrose Injection, Type 1, USP) is indicated as a source of water, electrolytes, and calories or as an alkalinizing agent.",
    "contraindications_original": "Important Administration Instructions \n                  \n                  \n                     \n                        •5% Dextrose and Electrolyte No. 48 Injection (Multiple Electrolytes and Dextrose Injection, Type 1, USP) is intended for intravenous administration using sterile equipment. \n                     \n                        •Do not connect flexible plastic containers in series in order to avoid air embolism due to possible residual air contained in the primary container. \n                     \n                        •Set the vent to the closed position on a vented intravenous administration set to prevent air embolism. \n                     \n                        •Use a dedicated line without any connections to avoid air embolism. \n                     \n                        •Do not pressurize intravenous solutions contained in flexible plastic containers to increase flow rates in order to avoid air embolism due to incomplete evacuation of residual air in the container. \n                     \n                        •Prior to infusion, visually inspect the solution for particulate matter and discoloration. The solution should be clear and there should be no precipitates. Do not administer unless solution is clear, and container is undamaged. \n                     \n                        •Do not administer 5% Dextrose and Electrolyte No. 48 Injection (Multiple Electrolytes and Dextrose Injection, Type 1, USP) simultaneously with blood through the same administration set because of the possibility of pseudoagglutination or hemolysis.\n                  \n                  \n                     Dosing Information\n                  \n                  The choice of product, dosage, volume, rate, and duration of administration is dependent upon the age, weight and clinical condition of the patient and concomitant therapy, and administration should be determined by a physician experienced in intravenous fluid therapy.\n                  \n                     Introduction of Additives \n                  \n                  Additives may be incompatible. \n                  Evaluate all additions to the plastic container for compatibility and stability of the resulting preparation. Consult with a pharmacist, if available. \n                  If, in the informed judgment of the physician, it is deemed advisable to introduce additives, use aseptic technique. Mix thoroughly when additives have been introduced. After addition, if there is a discoloration and/or the appearance of precipitates, insoluble complexes or crystals, do not use. Do not store solutions containing additives. Discard any unused portion.",
    "warningsAndPrecautions_original": "5% Dextrose and Electrolyte No. 48 Injection (Multiple Electrolytes and Dextrose Injection, Type 1, USP) in VIAFLEX plastic containers is available as shown below:\n                  \n                     \n                     \n                     \n                     \n                        \n                           \n                              \n                                 Code\n                              \n                           \n                           \n                              \n                                 Size (mL)\n                              \n                           \n                           \n                              \n                                 NDC\n                              \n                           \n                        \n                        \n                           \n                              2B2103 \n                           \n                           \n                               500 \n                           \n                           \n                               NDC 0338-0143-03 \n                           \n                        \n                        \n                           \n                           \n                           \n                        \n                     \n                  \n                  Exposure of pharmaceutical products to heat should be minimized. Avoid excessive heat. It is recommended the product be stored at room temperature (25°C); brief exposure up to 40°C does not adversely affect the product.",
    "adverseReactions_original": "5% Dextrose and Electrolyte No. 48 Injection (Multiple Electrolytes and Dextrose Injection, Type 1, USP) is contraindicated in patients \n                  \n                     \n                        •with a known hypersensitivity to the product (see \n                           WARNINGS\n                        )\n                     \n                        •with clinically significant hyperglycemia (see \n                           WARNINGS)"
}